ビットカジノ スロット
- December 16, 2024
- KYORIN and Bayer Enter into License Agreement for Novel Obstructive Sleep Apnea (OSA) Treatment
- December 6, 2024
- Notice of the relocation of the Nishinihon Distribution Center
- November 7, 2024
- Presentation document for Fiscal 2024 1st half (interim period) ビット カジノ 入金 ボーナスsults
- November 7, 2024
- Consolidated ビット カジノ 入金 ボーナスsults for the Six Months Ended September 30, 2024) [Japanese GAAP]
- November 7, 2024
- Consolidated ビット カジノ 入金 ボーナスsults for Second Quarter (Interim Period) of FY2024 - Supplementary Information
- August 2, 2024
- Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells
- July 31, 2024
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For the first quarter ended June 30, 2024) [Japanese GAAP]
- May 21, 2024
- Notice of Dividends of Retained Earnings
- May 10, 2024
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For fiscal year ended March 31, 2024) [Japanese GAAP]
- May 10, 2024
- Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ended March 31, 2024 (May 10 2024) - Supplementary Information
- April 15, 2024
- Starting Date of Operation at the New Head Office
- February 6, 2024
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For third quarter ended December 31, 2023) [Japanese GAAP]
- February 6, 2024
- Third Quarter Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ending March 31, 2024 (Feb 6, 2024) - Supplementary Information
- December 8, 2023
- Imidafenacin for Overactive Bladder Launched in Mexico
- November 8, 2023
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For second quarter ended September 30, 2023) [Japanese GAAP]
- November 8, 2023
- Second Quarter Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ending March 31, 2024 (Nov 8, 2022) - Supplementary Information
- November 8, 2023
- Notice of differences between Forecasts and Actual Results
- September 29, 2023
- Notice Regarding Implementation of voluntary Retirement Program
- August 2, 2023
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For the first quarter ended June 30, 2023) [Japanese GAAP]
- August 2, 2023
- 1Q Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ending March 31, 2024 (August 02, 2023) - Supplementary Information
- May 22, 2023
- Notice of Dividends of Retained Earnings
- May 11, 2023
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For fiscal year ended May 11, 2023) [Japanese GAAP]
- May 11, 2023
- Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ended March 31, 2023 (May 11, 2023) - Supplementary Information
- May 11, 2023
- Kyorin Announces New Long-Term Vision "Vision 110" and Medium-Term Business Plan "Vision 110 -Stage 1-"
- May 11, 2023
- Notice of Relocation of Head Office
- April 27, 2023
- KYORIN website has been relaunched today.
- April 3, 2023
- Notice of Absorption Type Merger of Wholly Owned Subsidiary KYORIN Pharmaceutical Co., Ltd and Change of Trade Name
- March 6, 2023
- KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries
- February 6, 2023
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For the third quarter ended December 31, 2022) [Japanese GAAP]
- February 6, 2023
- Third Quarter Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ending March 31, 2023 (Feb 6, 2023) - Supplementary Information
- November 9, 2022
- KYORIN and SUSMED conclude Collaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
- November 9, 2022
- Second Quarter Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information
- November 9, 2022
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For the second quarter ended September 30, 2022) [Japanese Standard]
- August 2, 2022
- Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc.
- August 2, 2022
- First Quarter Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
- August 2, 2022
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For the first quarter ended June 30, 2022) [Japanese Standard]
- June 17, 2022
- KYORIN Signs Joint Development and License Agreement for Genetically modified Adipocyte, Treatment Agent for Fabry Disease
- May 11, 2022
- Notice of Reduction of Capital Reserve
- May 11, 2022
- Consolidated ビット カジノ 入金 ボーナスsults for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information
- May 11, 2022
- Summary of Consolidated ビット カジノ 入金 ボーナスsults(For the fiscal year ended March 31, 2022) [Japanese Standard]